Solid Biosciences (SLDB) Expected to Announce Quarterly Earnings on Tuesday

Solid Biosciences (NASDAQ:SLDB) is expected to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to post earnings of ($0.43) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). On average, analysts expect Solid Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Solid Biosciences Stock Up 6.7%

Solid Biosciences stock traded up $0.54 during mid-day trading on Tuesday, reaching $8.56. 210,581 shares of the company’s stock were exchanged, compared to its average volume of 1,435,578. The business’s fifty day simple moving average is $8.44 and its 200 day simple moving average is $7.48. Solid Biosciences has a one year low of $3.79 and a one year high of $11.45. The firm has a market capitalization of $842.73 million, a PE ratio of -4.39 and a beta of 2.41.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Solid Biosciences in a research report on Friday, July 17th. HC Wainwright boosted their price target on shares of Solid Biosciences from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, June 3rd. Wedbush reduced their price target on shares of Solid Biosciences from $17.00 to $16.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Truist Financial upgraded shares of Solid Biosciences to a “strong-buy” rating in a report on Monday, April 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $18.00 price objective (up from $17.00) on shares of Solid Biosciences in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.11.

Institutional Trading of Solid Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vestal Point Capital LP boosted its holdings in shares of Solid Biosciences by 95.5% in the fourth quarter. Vestal Point Capital LP now owns 5,815,000 shares of the company’s stock worth $32,797,000 after acquiring an additional 2,840,000 shares during the period. Nantahala Capital Management LLC raised its stake in shares of Solid Biosciences by 505.4% during the 2nd quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company’s stock valued at $8,295,000 after purchasing an additional 1,421,968 shares during the period. Bank of America Corp DE lifted its holdings in Solid Biosciences by 2,150.4% during the 2nd quarter. Bank of America Corp DE now owns 824,600 shares of the company’s stock worth $4,016,000 after purchasing an additional 787,957 shares in the last quarter. Woodline Partners LP purchased a new stake in Solid Biosciences during the 1st quarter worth about $2,338,000. Finally, Armistice Capital LLC boosted its stake in Solid Biosciences by 134.0% in the 3rd quarter. Armistice Capital LLC now owns 936,000 shares of the company’s stock worth $5,775,000 after purchasing an additional 536,000 shares during the period. Institutional investors own 81.46% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical?stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle?stabilizing protein.

Solid’s lead investigational therapy, SGT?001, is a micro?dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno?associated virus (AAV) vector.